Last reviewed · How we verify
NCT05646017
Effect of Heatwave Over Glycemic Control in Patients With T1D
trial testing Intermittenly scanned continuous glucose monitoring in Type 1 Diabetes in 2,701 participants. Completed in 31 January 2023.
1 January 2023
Quick facts
| Lead sponsor | Castilla-La Mancha Health Service |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,701 |
| Start date | 15 December 2022 |
| Primary completion | 1 January 2023 |
| Estimated completion | 31 January 2023 |
| Sites | 9 locations across Spain |
Drugs / interventions tested
- Intermittenly scanned continuous glucose monitoring
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
Sponsor
Castilla-La Mancha Health Service — full company profile →
Who can join
Adults 18 to 99, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational study about effect of the greatest Spanish heatwave over glycemic contro in adult patients with type 1 Diabetes mellitus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05646017
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intermittenly scanned continuous glucose monitoring
Trials testing the same drug.
- NCT05918484 — Usefulness of Continuous Glucose Monitoring in MODY Diagnosis · completed
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other Castilla-La Mancha Health Service trials
Trials by the same sponsor.
- NCT06834334 — Clinical Effectiveness of Advanced Hybrid Closed-loop Systems for Achieving Time in Tight Range Among T1D Patients · completed
- NCT06466967 — Clinical Utility of Tight Objectives of Advanced Hybrid Closed-loop Systems Among Type 1 Diabetes Patients (TightT1AHCL) · completed
- NCT06214780 — Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas · completed
- NCT06222775 — Multicomponent Intervention on Lifestyle, Anthropometric Measurements, Glycemic Control and Quality of Life in Patients · NA · unknown
- NCT05918484 — Usefulness of Continuous Glucose Monitoring in MODY Diagnosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05646017 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Castilla-La Mancha Health Service
- Last refreshed: 10 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05646017.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing